What issues should patients with diabetes pay attention to when using capmatinib (Touradida)?

Capmatinib (capmatinib) is a targeted drug for non-small cell lung cancer targeting METexon14 skipping mutations or MET high expression. It blocks tumor cell proliferation and metastasis signals by inhibiting the activity of MET receptor tyrosine kinase. For patients with diabetes, the use of capmatinib requires special attention to glycemic control and potential drug interactions, as glycemic fluctuations during cancer treatment may exacerbate the risk of complications.

Patients with diabetes should monitor blood glucose levels regularly while taking capmatinib. Some patients may develop elevated blood sugar or metabolic disorders, especially when taking long-term medication or taking concomitant glucocorticoids. In order to reduce blood sugar fluctuations, you should strictly follow the diet and medication regimen prescribed by your doctor, adjust the dosage of hypoglycemic drugs if necessary, and closely observe symptoms of hypoglycemia or hyperglycemia.

In addition, capmatinib may cause edema, weight gain, and changes in renal function. These factors have a certain impact on the heart and kidney health of patients with diabetes. Patients should regularly monitor their weight, blood pressure, kidney function and electrolyte levels during treatment, and seek medical attention promptly if any abnormalities occur. Maintaining regular exercise and eating properly are also important measures to reduce the risk of cardiovascular complications.

Finally, before using capmatinib, diabetic patients should inform their doctors in detail about all anti-diabetic drugs and other chronic disease treatment options they are using to avoid drug interactions. During the treatment process, patients should maintain close communication with the medical team to ensure simultaneous management of blood sugar, cardiorenal function, and tumor efficacy, so as to maximize the safety and effectiveness of treatment.

Reference link:https://www.drugs.com